var data={"title":"Tadalafil: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tadalafil: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7008?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tadalafil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tadalafil: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224586\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Adcirca;</li>\n      <li>Cialis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F854896\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Adcirca;</li>\n      <li>Cialis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224603\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Phosphodiesterase-5 Enzyme Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224587\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Benign prostatic hyperplasia (with or without concomitant erectile dysfunction) (Cialis):</b> Oral: 5 mg once daily. <b>Note:</b> When tadalafil is used with finasteride to initiate BPH therapy, the recommended duration of therapy is &le;26 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dosing adjustment with concomitant medications:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alpha<sub>1</sub>-blockers: Not recommended for use in combination with alpha-blockers for the treatment of BPH.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CYP3A4 inhibitors (strong): 2.5 mg once daily; maximum: 2.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Erectile dysfunction (Cialis):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>As-needed dosing:</i> 10 mg at least 30 minutes prior to anticipated sexual activity as one single dose and not more than once daily. Dose may be adjusted based on tolerability (dosing range: 5 to 20 mg). <b>Note:</b> Erectile function may be improved for up to 36 hours following a single dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Once-daily dosing:</i> 2.5 mg once daily at approximately the same time daily without regard to timing of sexual activity. Dose may be adjusted based on tolerability (dosage range:  2.5 to 5 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dosing adjustment with concomitant medications:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alpha<sub>1</sub>-blockers: Patients should be stable on alpha-blocker therapy prior to initiating tadalafil treatment, and tadalafil should be initiated at the lowest recommended dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CYP3A4 inhibitors (strong):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>As-needed dosing: </i>Maximum: 10 mg, not more frequently than every 72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Once-daily dosing: </i>Maximum: 2.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Pulmonary arterial hypertension (Adcirca):</b> Oral: 40 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dosing adjustment with concomitant medications:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Concurrent use with ritonavir:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initiation of tadalafil in patients currently receiving ritonavir for at least 1 week: Initiate tadalafil at 20 mg once daily; increase to 40 mg once daily based on individual tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initiation of  ritonavir in patients currently receiving tadalafil: Discontinue tadalafil at least 24 hours prior to the initiation of ritonavir. After at least 1 week of ritonavir, resume tadalafil at 20 mg once daily; increase to 40 mg once daily based on individual tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Raynaud phenomenon (off-label use):</b> Oral: 20 mg every other day. Clinical trials ranged from 4 to 8 weeks as monotherapy or as adjunctive therapy to vasodilator therapy (eg, calcium channel blockers, angiotensin-converting enzyme inhibitor ([ACEI] angiotensin receptor blocker [ARB]) (Shenoy 2010; Roustit 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224588\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. No dose adjustment for patients &gt;65 years of age in the absence of renal or hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224589\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Benign prostatic hyperplasia (with or without concomitant erectile dysfunction) (Cialis):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;51 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 50 mL/minute: Initial: 2.5 mg once daily; maximum: 5 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: Use not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD requiring hemodialysis: Use not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Erectile dysfunction (Cialis):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>As-needed use:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;51 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 50 mL/minute: Initial: 5 mg once daily; maximum: 10 mg (not more frequently than every 48 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Maximum: 5 mg (not more frequently than every 72 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD requiring hemodialysis: Maximum: 5 mg (not more frequently than every 72 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Once-daily use:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;31 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Use not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD requiring hemodialysis: Use not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Pulmonary arterial hypertension (Adcirca): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 31 to 80 mL/minute: Initial: 20 mg once daily; increase to 40 mg once daily based on individual tolerability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &le;30 mL/minute: Avoid use due to increased tadalafil exposure, limited clinical experience, and lack of ability to influence clearance by dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD requiring hemodialysis: Avoid use due to increased tadalafil exposure, limited clinical experience, and lack of ability to influence clearance by dialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224590\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Benign prostatic hyperplasia (with or without concomitant erectile dysfunction) (Cialis):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate hepatic impairment (Child-Pugh class A or B): Use with caution; the use of tadalafil for once-daily use has not been extensively evaluated in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe hepatic impairment (Child-Pugh class C): Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Erectile dysfunction (Cialis):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>As-needed use:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate impairment (Child-Pugh class A or B): Use with caution; dose should not exceed 10 mg once daily. The use of tadalafil once per day has not been evaluated extensively in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe impairment (Child-Pugh class C): Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Once-daily use:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate impairment (Child-Pugh class A or B): Use with caution; the use of tadalafil for once-daily use has not been extensively evaluated in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe impairment (Child-Pugh class C): Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Pulmonary arterial hypertension (Adcirca): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate hepatic impairment (Child-Pugh class A or B): Use with caution; consider initial dose of 20 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe hepatic impairment (Child-Pugh class C): Avoid use; has not been studied in patients with severe hepatic cirrhosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224562\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adcirca: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cialis: 2.5 mg, 5 mg, 10 mg, 20 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224549\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224565\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adcirca: Administer daily dose all at once; dividing doses throughout the day is not advised.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cialis: Do not split tablets; the entire dose should be taken. When used on an as-needed basis, should be taken at least 30 minutes prior to sexual activity. When used on a once-daily basis, should be taken at the same time each day, without regard to timing of sexual activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224564\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Benign prostatic hyperplasia (Cialis only):</b> Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Erectile dysfunction (Cialis only):</b> Treatment of erectile dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Erectile dysfunction and benign prostatic hyperplasia (Cialis only):</b> Treatment of erectile dysfunction and the signs and symptoms of BPH. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary arterial hypertension (Adcirca only):</b> Treatment of pulmonary arterial hypertension (World Health Organization group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with New York Heart Association (NYHA) functional class II to III symptoms and etiologies of idiopathic or heritable pulmonary arterial hypertension (61%) or pulmonary arterial hypertension associated with connective tissue diseases (23%).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46924098\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Raynaud Phenomenon</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6472503\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tadalafil may be confused with sildenafil, vardenafil</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adcirca may be confused with Advair Diskus, Advair HFA, Advicor</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224554\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">For erectile dysfunction, similar adverse events are reported with once-daily versus intermittent dosing, but are generally lower than with doses used intermittently.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (1% to 13%; dose related)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (3% to 42%; dose related), limb pain (1% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (1% to 13%), nausea (10% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (1% to 14%; dose related), back pain (2% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Respiratory tract infection (3% to 13%), nasopharyngitis (2% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (1% to 3%), angina pectoris (&lt;2%), chest pain (&lt;2%), facial edema (&lt;2%), hypotension (&lt;2%), myocardial infarction (&lt;2%), orthostatic hypotension (&lt;2%), palpitations (&lt;2%), peripheral edema (&lt;2%), syncope (&lt;2%), tachycardia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (&lt;2%), drowsiness (&lt;2%), fatigue (&lt;2%), hypoesthesia (&lt;2%), insomnia (&lt;2%), pain (&lt;2%), paresthesia (&lt;2%), vertigo (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (&lt;2%), pruritus (&lt;2%), skin rash (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastroenteritis (viral; 3% to 5%), gastroesophageal reflux disease (1% to 3%), abdominal pain (1% to 2%), diarrhea (1% to 2%), dysphagia (&lt;2%), esophagitis (&lt;2%), gastritis (&lt;2%), hemorrhoidal bleeding (&lt;2%), loose stools (&lt;2%), upper abdominal pain (&lt;2%), vomiting (&lt;2%), xerostomia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Spontaneous erections (&lt;2%), urinary tract infection (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Rectal hemorrhage (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal liver function tests (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (&lt;2%), neck pain (&lt;2%), weakness (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (&lt;2%), conjunctival hyperemia (&lt;2%), conjunctivitis (&lt;2%), eye pain (&lt;2%), lacrimation (&lt;2%), periorbital swelling (&lt;2%), vision color changes (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Hearing loss (&lt;2%), tinnitus (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal insufficiency (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasal congestion (&le;9%), flu-like symptoms (2% to 5%), cough (2% to 4%), bronchitis (&le;2%), dyspnea (&lt;2%), epistaxis (&lt;2%), pharyngitis (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Amnesia (transient global), basal cell carcinoma, cerebrovascular accident, exfoliative dermatitis, malignant melanoma, migraine, optic neuropathy (nonarteritic ischemic), priapism, retinal artery occlusion, retinal vein occlusion, seizure, Stevens-Johnson syndrome, urticaria, visual field loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224568\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serious hypersensitivity to tadalafil or any component of the formulation; concurrent use of organic nitrate (regularly and/or intermittently) or guanylate cyclase stimulators (eg, riociguat).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Previous episode of nonarteritic anterior ischemic optic neuropathy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224552\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anginal chest pain: Patients experiencing anginal chest pain after tadalafil administration should seek immediate medical attention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Color discrimination: May cause dose-related impairment of color discrimination. Use caution in patients with retinitis pigmentosa; a minority have genetic disorders of retinal phosphodiesterases (no safety information available).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hearing loss: Sudden decrease or loss of hearing has been reported rarely; hearing changes may be accompanied by tinnitus and dizziness. Instruct patients to seek medical assistance for sudden decrease in hearing or loss of hearing. A direct relationship between therapy and hearing loss has not been determined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Decreases in blood pressure may occur due to vasodilator effects; use with caution in patients with left ventricular outflow obstruction (aortic stenosis or hypertrophic obstructive cardiomyopathy); may be more sensitive to hypotensive actions. Concurrent use with alpha-adrenergic antagonist therapy may cause symptomatic hypotension; patients should be hemodynamically stable prior to initiating therapy at the lowest possible dose. Patients should avoid or limit concurrent substantial ethanol consumption as this may increase the risk of symptomatic hypotension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism: Painful erection &gt;6 hours in duration has been reported (rarely). Instruct patient to seek medical assistance for erection lasting &gt;4 hours. Use with caution in patients who have conditions which may predispose them to priapism (eg, sickle cell anemia, multiple myeloma, leukemia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vision loss: Vision loss (rare) may be a sign of nonarteritic anterior ischemic optic neuropathy (NAION); causal relationship to PDE5 inhibitors not established. Instruct patients to discontinue therapy and seek medical assistance for sudden loss of vision in one or both eyes. Patients who have already experienced NAION are at an increased risk of recurrence. Other risk factors for NAION include low cup-to-disc ratio (&quot;crowded disc&quot;), CAD, diabetes, hypertension, hyperlipidemia, smoking, and &gt;50 years of age. Use with caution in these patients and only when the benefits outweigh the risks. Safety has not been evaluated in patients with known hereditary degenerative retinal disorders (eg, retinitis pigmentosa); use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anatomical penis deformation: Use with caution in patients with anatomical deformation of the penis (angulation, cavernosal fibrosis, or Peyronie disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders; safety and efficacy have not been established. <i> In vitro</i> studies have suggested a decreased effect on platelet aggregation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use is not recommended in patients with hypotension (&lt;90/50 mm Hg), uncontrolled hypertension (&gt;170/100 mm Hg), NYHA class II-IV heart failure within the last 6 months, uncontrolled arrhythmias, stroke within the last 6 months, MI within the last 3 months, unstable angina or angina during sexual intercourse; safety and efficacy have not been evaluated in these patients. Safety and efficacy in PAH have not been evaluated in patients with clinically significant aortic and/or mitral valve disease, life-threatening arrhythmias, hypotension (&lt;90/50 mm Hg), uncontrolled hypertension, significant left ventricular dysfunction, pericardial constriction, restrictive or congestive cardiomyopathy, symptomatic coronary artery disease. Use caution in patients with left ventricular outflow obstruction (eg, aortic stenosis, hypertrophic obstructive cardiomyopathy); may be more sensitive to vasodilator effects. There is a degree of cardiac risk associated with sexual activity; therefore, physicians may wish to consider the cardiovascular status of their patients prior to initiating any treatment for erectile dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment; dosage adjustment/limitation is needed. Use is not recommended in patients with severe hepatic impairment or cirrhosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peptic ulcer disease: Use with caution in patients with active peptic ulcer disease because of effect on platelets (bleeding); safety and efficacy have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary veno-occlusive disease (PVOD): Pulmonary vasodilators may exacerbate the cardiovascular status in patients with PVOD. Use is not recommended; no clinical data exists in patients with PVOD. In patients with unrecognized PVOD, signs of pulmonary edema should prompt investigation into this diagnosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment/limitation is needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nitrates: Concomitant use (regularly/intermittently) with all forms of nitrates is contraindicated. Nitrate-mediated vasodilation is markedly exaggerated and prolonged in the presence of PDE-5 inhibitors. When tadalafil is used for BPH, erectile dysfunction, or PAH and nitrate administration is medically necessary (eg, chest pain refractory to other treatments) following the use of tadalafil, at least 48 hours should elapse after the tadalafil dose and nitrate administration. When used for PAH, per the manufacturer, nitrate may be administered within 48 hours of tadalafil. For both situations, administration of nitrates should only be done under close medical supervision with hemodynamic monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Potential underlying causes of erectile dysfunction or BPH should be evaluated prior to treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224597\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224556\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10108&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers (Nonselective): Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Alpha1-Blockers (Nonselective).  Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers (Uroselective): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alprostadil: Phosphodiesterase 5 Inhibitors may enhance the adverse/toxic effect of Alprostadil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amyl Nitrite: Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Amyl Nitrite. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Tadalafil. Management: Avoid tadalafil when used for treatment of pulmonary arterial hypertension in patients receiving boceprevir.  Tadalafil for erectile dysfunction should be limited to 10 mg every 72 hours with close monitoring for tadalafil toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Phosphodiesterase 5 Inhibitors may increase the serum concentration of Bosentan.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Tadalafil. Management: Recommendations for use of tadalafil in patients also receiving cobicistat vary by tadalafil indication and country. See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Tadalafil. Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tadalafil. Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.<b> Exceptions: </b>Ritonavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Management: No empiric dosage adjustments are recommended with concomitant therapy; however, dose of the phosphodiesterase inhibitor may need to be altered based on clinical response.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Tadalafil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Tadalafil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Tadalafil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lorcaserin: May enhance the adverse/toxic effect of Phosphodiesterase 5 Inhibitors. Specifically, the risk of developing priapism may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Nitroprusside. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of other Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May increase the serum concentration of Tadalafil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of Tadalafil. Management: Recommendations regarding use of tadalafil in patients also receiving ritonavir may vary based on indication and/or international labeling. Consult appropriate product labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sapropterin: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Tadalafil. Management: Concurrent use of tadalafil for treatment of pulmonary arterial hypertension is contraindicated with telaprevir.  Tadalafil for erectile dysfunction should be limited to 10 mg per 72 hours, with close monitoring for tadalafil toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Tadalafil.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vasodilators (Organic Nitrates): Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Vasodilators (Organic Nitrates). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Tadalafil.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224583\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Rate and extent of absorption are not affected by food. Grapefruit juice may increase serum levels/toxicity of tadalafil. Management: Use of grapefruit juice should be limited or avoided.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224558\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224571\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Tadalafil likely crosses the placenta (Sakamoto 2016). Women with pulmonary arterial hypertension are encouraged to avoid pregnancy (McLaughlin 2009; Taichman 2014). Less than 0.0005% is found in the semen of healthy males.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17916818\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if tadalafil is present in breast milk. The manufacturer recommends that caution be exercised when administering tadalafil to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224560\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, response and adverse effects; urine flow, PSA</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224551\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BPH: Exact mechanism unknown; effects likely due to PDE-5 mediated reduction in smooth muscle and endothelial cell proliferation, decreased nerve activity, and increased smooth muscle relaxation and tissue perfusion of the prostate and bladder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erectile dysfunction: Does not directly cause penile erections, but affects the response to sexual stimulation. The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation and inflow of blood to the corpus cavernosum. Tadalafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE-5), which is responsible for degradation of cGMP in the corpus cavernosum; when sexual stimulation causes local release of NO, inhibition of PDE-5 by tadalafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum. At recommended doses, it has no effect in the absence of sexual stimulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAH: Inhibits phosphodiesterase type 5 (PDE-5) in smooth muscle of pulmonary vasculature where PDE-5 is responsible for the degradation of cyclic guanosine monophosphate (cGMP). Increased cGMP concentration results in pulmonary vasculature relaxation; vasodilation in the pulmonary bed and the systemic circulation (to a lesser degree) may occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224567\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Within 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect (pulmonary artery vasodilation): 75 to 90 minutes (Ghofrani 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Erectile dysfunction: Up to 36 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 63 to 77 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 94% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic, via CYP3A4 to metabolites (inactive) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 15 to 17.5 hours; Pulmonary hypertension (not receiving bosentan): 35 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: ~2 hours (range: 30 minutes to 6 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (~61%, predominantly as metabolites); urine (~36%, predominantly as metabolites) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224570\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Adcirca Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (60): $4,809.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cialis Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (15): $205.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $410.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $2,404.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $2,404.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224573\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>36 Horas (PY);</li>\n      <li>Adafil (BD);</li>\n      <li>Adcirca (AT, AU, BB, BE, BR, CZ, DK, EE, ES, FR, GB, HR, HU, IE, IS, JP, LT, LU, MT, MX, NL, NO, PL, PT, RO, SE, SI, SK);</li>\n      <li>Agitafil (VN);</li>\n      <li>Cendom (KR);</li>\n      <li>Cendom Orally Soluble Film (KR);</li>\n      <li>Cialis (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BR, BS, CH, CI, CL, CN, CO, CY, CZ, DE, DK, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, HR, HU, ID, IE, IL, IS, IT, JM, JO, JP, KE, KR, KW, LB, LR, LT, LU, LV, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, PE, PH, PL, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, TH, TN, TR, TT, TW, TZ, UG, VE, VN, ZA, ZM, ZW);</li>\n      <li>Ciaton (BD);</li>\n      <li>Digram (PY);</li>\n      <li>Duralis (LB);</li>\n      <li>Erotadil (VN);</li>\n      <li>Exerdya (HU);</li>\n      <li>Forzest (IN);</li>\n      <li>Glofil (LK);</li>\n      <li>GODN Orodispersible Film (KR);</li>\n      <li>Greseo Powd. (KR);</li>\n      <li>Gugu Chew (KR);</li>\n      <li>Lanrextan (AT);</li>\n      <li>Mega Joy (BD);</li>\n      <li>Megafil (LK);</li>\n      <li>Megafort (VN);</li>\n      <li>Pasport (TR);</li>\n      <li>Sialis (UA);</li>\n      <li>Snafi (AE, BH, KW, QA, SA);</li>\n      <li>Sunka (KR);</li>\n      <li>Tadacip (LK);</li>\n      <li>Tadaf (LK);</li>\n      <li>Tagra (LB);</li>\n      <li>Viev (BD);</li>\n      <li>Yesgra (KR);</li>\n      <li>Zenavil (MT);</li>\n      <li>Zydalis (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adcirca (tadalafil) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adcirca (tadalafil) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andersson KE, de Groat WC, McVary KT, et al, &quot;Tadalafil for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Pathophysiology and Mechanism(s) of Action,&quot; <i>Neurourol Urodyn</i>, 2011, 30(3):292-301.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson JL, Adams CD, Antman EM, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(23):e663-e828. doi: 10.1161/CIR.0b013e31828478ac.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/23630129/pubmed\" target=\"_blank\" id=\"23630129\">23630129</a>]</span><span class=\"doi\">10.1161/CIR.0b013e31828478ac</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheitlin MD, Hutter AM Jr, Brindis RG, et al, &ldquo;Use of Sildenafil (Viagra&reg;) in Patients With Cardiovascular Disease,&rdquo; <i>J Am Coll Cardiol</i>, 1999, 33(1):273-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/9935041/pubmed\" target=\"_blank\" id=\"9935041\">9935041</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cialis (tadalafil) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cialis (tadalafil) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Curran M and Keating G, &ldquo;Tadalafil,&rdquo; <i>Drugs</i>, 2003, 63(20):2203-12; discussion 2213-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/14498756/pubmed\" target=\"_blank\" id=\"14498756\">14498756</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daugan A, Grondin P, Ruault C, et al, &ldquo;The Discovery of Tadalafil: A Novel and Highly Selective PDE-5 Inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1&prime;,2&prime;:1,6]pyrido[3,4-b]indole-1,4-dione Analogues,&rdquo; <i>J Med Chem</i>, 2003, 46(21):4533-42.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fraunfelder FW, &ldquo;Visual Side Effects Associated With Erectile Dysfunction Agents,&rdquo; <i>Am J Ophthal</i>, 2005, 140 (4):723-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/16226525/pubmed\" target=\"_blank\" id=\"16226525\">16226525</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galie N, Brundage BH, Ghofrani HA, et al, &ldquo;Tadalafil Therapy for Pulmonary Arterial Hypertension,&rdquo; <i>Circulation</i>, 2009, 119(22):2894-903.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/19470885/pubmed\" target=\"_blank\" id=\"19470885\">19470885</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ghofrani HA, Voswinckel R, Reichenberger F, et al, &ldquo;Differences in Hemodynamic and Oxygenation Responses to Three Different Phosphodiesterase-5 Inhibitors in Patients with Pulmonary Arterial Hypertension,&rdquo; <i>J Am Coll Cardiol</i>, 2004, 44(7):1488-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/15464333/pubmed\" target=\"_blank\" id=\"15464333\">15464333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jackson G, Rosen RC, Kloner RA, et al, &ldquo;The Second Princeton Consensus on Sexual Dysfunction and Cardiac Risk: New Guidelines for Sexual Medicine,&rdquo; <i>J Sex Med</i>, 2006, 3(1):28-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/16409215/pubmed\" target=\"_blank\" id=\"16409215\">16409215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kloner RA, Mitchell M, and Emmick JT, &ldquo;Cardiovascular Effects of Tadalafil,&rdquo; <i>Am J Cardiol</i>, 2003, 92(9A):37M-46M.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/14609622/pubmed\" target=\"_blank\" id=\"14609622\">14609622</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kloner RA, Mitchell M, and Emmick JT, &ldquo;Cardiovascular Effects of Tadalafil in Patients on Common Antihypertensive Therapies,&rdquo; <i>Am J Cardiol</i>, 2003, 92(9A):47M-57M.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/14609623/pubmed\" target=\"_blank\" id=\"14609623\">14609623</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loeb S, Folkvaljon Y, Lambe M, et al. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. <i>JAMA</i>. 2015;313(24):2449-2455.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/26103029/pubmed\" target=\"_blank\" id=\"26103029\">26103029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association,&rdquo; <i>J Am Coll Cardiol</i>, 2009, 53(17):1573&ndash;619.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/19389575/pubmed\" target=\"_blank\" id=\"19389575\">19389575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McVary KT, &ldquo;Clinical Practice. Erectile Dysfunction,&rdquo; <i>N Engl J Med</i>, 2007, 357(24):2472-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/18077811/pubmed\" target=\"_blank\" id=\"18077811\">18077811</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. <i>Mayo Clin Proc</i>. 2012;87(8):766-778. doi: 10.1016/j.mayocp.2012.06.015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/22862865/pubmed\" target=\"_blank\" id=\"22862865\">22862865</a>]</span><span class=\"doi\">10.1016/j.mayocp.2012.06.015</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Padma-Nathan H, &ldquo;Efficacy and Tolerability of Tadalafil, A Novel Phosphodiesterase 5 Inhibitor, in Treatment of Erectile Dysfunction,&rdquo; <i>Am J Cardiol</i>, 2003, 92(9A):19-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/14609620/pubmed\" target=\"_blank\" id=\"14609620\">14609620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud&rsquo;s phenomenon: systematic review and meta-analysis of randomized trials. <i>Ann Rheum Dis.</i> 2013;72(10):1696-1699.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/23426043/pubmed\" target=\"_blank\" id=\"23426043\">23426043</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sakamoto M, Osato K, Kubo M, Nii M, et al. Early-onset fetal growth restriction treated with the long-acting phosphodiesterase-5 inhibitor tadalafil: a case report. <i>J Med Case Rep.</i> 2016;10(1):317. doi: 10.1186/s13256-016-1098-x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/27821175/pubmed\" target=\"_blank\" id=\"27821175\">27821175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. <i>Rheumatology (Oxford). </i>2010;49(12):2420-2428.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/20837499/pubmed\" target=\"_blank\" id=\"20837499\">20837499</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. <i>Chest</i>. 2014;146(2):449-475. doi: 10.1378/chest.14-0793.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tadalafil-drug-information/abstract-text/24937180/pubmed\" target=\"_blank\" id=\"24937180\">24937180</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10108 Version 178.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F224586\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F854896\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F224603\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F224587\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F224588\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F224589\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F224590\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F224562\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F224549\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F224565\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F224564\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F46924098\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6472503\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F224554\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F224568\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F224552\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F224597\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F224556\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F224583\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F224558\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F224571\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F17916818\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F224560\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F224551\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F224567\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F224570\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F224573\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10108|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tadalafil-patient-drug-information\" class=\"drug drug_patient\">Tadalafil: Patient drug information</a></li></ul></div></div>","javascript":null}